


Welcome to the October edition

[View this email in a browser](#)



Welcome to the October edition of the **Experts in MS** newsletter.

As we move into autumn, we're excited to share some valuable updates and opportunities to enhance your practice and knowledge in MS care.



Webinars - Improving Services

We're delighted to offer three insightful webinars, each addressing key aspects of MS care.

Somerset Neuro-rehabilitation service review

- Wednesday, 13 November, 6:30 PM
- Julie Jones from Somerset NHS Foundation Trust, will share valuable insights into their comprehensive service review. And the compelling case for change that convinced the ICB.

[Register for the Neurorehabilitation webinar →](#)

Continence Care in Neurology: 18 months on


- Wednesday, 20 November, 7:00-8:30 PM
- Follow up on MS consensus bladder and bowel pathway
- Expert speakers discuss progress and challenges
- Interactive Q&A session

[Register for the Continence care webinar →](#)

Developing an integrated care model for people with long-term neurological condition

- Wednesday, 6 November, 7:00 - 8:15 PM
- Sandra Bartolomeu Pires presents her groundbreaking PhD research on integrated care for long-term neurological conditions.
- Intervention that improves joined-up care for families living with Huntington's disease (and other neurological conditions)
- Identifying obstacles to change, and how to overcome them
- Collaborative discussion on developing more effective care models

[Register for the Integrated care model webinar →](#)



Research News

MS-STAT2 trials results

The trial shows that simvastatin is not an effective treatment for secondary progressive MS.

The results of the MS-STAT2 trial were announced by Professor Jeremy Chataway at the ECTRIMS research conference in Copenhagen.

[Find out more about the MS-STAT2 trial results →](#)

HERCULES trial: Tolebrutinib shows promise for non-active SPMS

For the first time, a phase 3 trial has shown a drug can slow down disability progression in people with secondary progressive MS who don't have relapses. In two other phase 3 trials, tolebrutinib also slowed progression in relapsing MS.

[Find out more about tolebrutinib trial →](#)

UK MS Data Register Academy

Boost your MS research with cutting-edge big data skills. This course equips health researchers, ECRs, and professionals from NHS, academia, and medical charities with essential tools for population health data

analysis.

Dates: 21 - 22 November

Location: MS Society offices, London

Cost: £50 for two days of teaching (lunch and refreshments included)

[Find out more and book your place →](#)



Information

Updated information booklets

We've updated our booklets - 'What is MS?' and 'Moving more with MS'.

[>> Download 'What is MS?'](#)

[>> Download 'Moving more with MS'](#)

Too hot, too cold

We caught up with temperature and MS researcher Davide Filingeri. He explains why some people with MS are affected by heat, by the cold, or by both.

[>> Read the interview](#)

Help people with MS find financial support

With colder weather arriving, and energy bills increasing, you can signpost people with MS and their families to our information. Our

benefits advisers can help make sure people get all the support that's available.

[>> Find financial support information](#)

Tell us what you need

Let us know the kind of information and resources you'd like to receive, and if you found our information useful.

[Have your say>>](#)

Get in touch and spread the word!

We want to hear from you. If you want to spotlight your services, have ideas for content, or would like to submit articles, [email the team](#).

Please do share this with a friend or colleague, it's easy to sign up.

Let's stop MS together



You are receiving this email because you have opted in to receive professional network communications from us.

You are subscribed as: phil.seddon@mssociety.org.uk

Tell us if you'd like to unsubscribe

[Privacy & Cookie Notice](#)

Registered charity nos. 1139257 / SC041990.
Registered as a limited company in England and Wales 07451571.

